Ignite Creation Date:
2025-12-24 @ 9:31 PM
Ignite Modification Date:
2026-02-24 @ 2:29 PM
Study NCT ID:
NCT06782932
Status:
RECRUITING
Last Update Posted:
2025-12-03
First Post:
2025-01-14
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Pancreatic Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Balstilimab | View |
| None | AGEN2373 | View |
| None | KRAS peptide vaccine | View |
| None | peptide vaccine | View |
| None | Poly-ICLC | View |
| None | GVAX | View |
| None | Cyclophosphamide | View |
| None | Immunotherapy | View |
| None | Anti-PD-1 (anti-check point inhibitor) | View |
| None | PD-L1 (check point inhibitor) | View |
| None | Anti-CD137 | View |
| None | Cancer vaccine | View |
| None | Pancreatic Cancer | View |
| None | Pancreatic Ductal Adenocarcinoma (PDAC) | View |
| None | Adenocarcinoma | View |
| None | Carcinoma | View |
| None | Pancreas | View |
| None | mKRASvax | View |